MetaVia Inc.
Close on Oct 19, 2026
- Market cap
- $7.30M
- P/E (TTM)
- –
- Dividend yield
- –
About MetaVia
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biotechnology business primarily focused on researching and developing novel pharmaceuticals to treat cardiometabolic diseases. Its core clinical pipeline comprises two main drug candidates: vanoglipel (DA-1241), an orally administered GPR119 agonist being evaluated for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus, and DA-1726, an oxyntomodulin analog targeting the glucagon-like peptide-1 receptor and glucagon receptor for the treatment of obesity. The business also maintains four legacy programs spanning viral, neurodegenerative, and cardiometabolic indications, which it considers for out-licensing and divestiture opportunities, including an out-licensed candidate for painful diabetic neuropathy. Its primary end customers are prospective patients suffering from cardiometabolic disorders.
The company operates predominantly in the United States, where its clinical trials and research activities take place. Its corporate headquarters, precise facility counts, and broader geographic footprint are not stated in the provided text.
Summary of the business section of MetaVia's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MetaVia Inc.
- Headquarters
- Cambridge, MA
- Address
- 545 Concord Avenue, Suite 210 02138
- Phone
- (857) 702-9600
- Website
- metaviatx.com
- Employees
- 9, Dec 31, 2024
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., Boston Massachusetts
Stock & identifiers
- Ticker
- MTVA
- Exchange
- Nasdaq
- IPO date
- Aug 8, 2016
- Shares outstanding
- 7M, Aug 3, 2026
- Public float
- $3.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-11 reverse, Dec 31, 2025; 1-for-11 reverse, Dec 5, 2025; 1-for-8 reverse, Mar 28, 2024; 1-for-8 reverse, Dec 21, 2023; 1-for-30 reverse, Nov 14, 2022; 1-for-30 reverse, Sep 13, 2022; 1-for-2.75 reverse, Mar 30, 2020; 1-for-25 reverse, Dec 31, 2019
- SEC CIK
- 1638287
- CUSIP
- 64132R503
- ISIN
- US64132R5037
- EIN
- 47-2389984
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Hyung Heon Kim | CEO & President, Director | 37,545 |
| Marshall H. Woodworth | Chief Financial Officer | 30,734 |
| Andrew I. Koven | Director | 21,339 |
| Michael Salsbury | Director | 21,338 |
| D. Gordon Strickland | Director | 21,339 |
| Mark A. Glickman | Director | 20,629 |
| Jason L. Groves | Director | 21,338 |
| James Patrick Tursi | Director | 20,568 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr Gil Price | $0 | $0 | $562.99K | $13 | – |
| FY2025 Hyung Heon Kim | $756.33K | $723.64K | $562.99K | $13 | – |
| FY2025 Joseph Hooker | $0 | $0 | $562.99K | $13 | – |
| FY2024 Dr Gil Price | $0 | $0 | $774.70K | $35 | – |
| FY2024 Hyung Heon Kim | $716.40K | $647.14K | $774.70K | $35 | – |
| FY2024 Joseph Hooker | $0 | $0 | $774.70K | $35 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2024, we had nine full-time employees.”
Corporate history
Events identified from SEC filings